Abstract
OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P
| Original language | English |
|---|---|
| Pages (from-to) | 34-38 |
| Number of pages | 5 |
| Journal | Diabetes Care |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. / Anderson, Robert J.; Bahn, Gideon D.; Moritz, Thomas E.; Kaufman, Derrick; Abraira, Carlos; Duckworth, William.
In: Diabetes Care, Vol. 34, No. 1, 01.2011, p. 34-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial
AU - Anderson, Robert J.
AU - Bahn, Gideon D.
AU - Moritz, Thomas E.
AU - Kaufman, Derrick
AU - Abraira, Carlos
AU - Duckworth, William
PY - 2011/1
Y1 - 2011/1
N2 - OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P
AB - OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P
UR - http://www.scopus.com/inward/record.url?scp=79951713554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951713554&partnerID=8YFLogxK
U2 - 10.2337/dc10-1420
DO - 10.2337/dc10-1420
M3 - Article
C2 - 21059830
AN - SCOPUS:79951713554
VL - 34
SP - 34
EP - 38
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 1
ER -